论文部分内容阅读
目的探讨血小板源性生长因子C(PDGF-C)在晚期非小细胞肺癌中的表达及临床意义。方法采用免疫组织化学方法对170例经病理证实的初治晚期NSCLC标本进行分析,检测PDGF-C的表达水平,并给予患者重组人血管内皮抑素(恩度)联合化疗。观察化疗有效率、疾病控制率、1年生存率及2年生存率。结果腺癌患者恩度联合化疗有效率为60.0%,疾病控制率为80.9%,其中PDGF-C表达阳性的腺癌患者恩度联合化疗有效率为59.2%(45/76),疾病控制率为81.6%(62/76),1年生存率和2年的生存率分别为68.4%和27.6%。PDGF-C表达阴性的腺癌患者1年生存率和2年的生存率分别为66.7%和28.2%。结论 PDGF-C在肺腺癌中的表达阳性率较高,PDGF-C表达阳性的乳头型或腺泡为主型的腺癌患者恩度联合化疗有效率虽未能提高,但是这类患者1、2年的生存率明显提高,预后较好。
Objective To investigate the expression and clinical significance of platelet-derived growth factor C (PDGF-C) in advanced non-small cell lung cancer. Methods Immunohistochemical method was used to analyze 170 cases of newly diagnosed advanced non-small cell lung cancer (NSCLC) specimens. The expression of PDGF-C was detected and the patients were treated with recombinant human endostatin (Endostar) combined with chemotherapy. To observe the chemotherapy efficiency, disease control rate, 1-year survival rate and 2-year survival rate. Results The total effective rate of combined chemotherapy for patients with adenocarcinoma was 60.0%, and the disease control rate was 80.9%. The positive rate of combined chemotherapy of adenocarcinoma with positive PDGF-C expression was 59.2% (45/76) and the rate of disease control was 81. 6% (62/76), 1-year survival rate and 2-year survival rate were 68.4% and 27.6% respectively. The 1-year survival rate and 2-year survival rate of patients with negative PDGF-C expression were 66.7% and 28.2%, respectively. Conclusions The positive rate of PDGF-C expression in lung adenocarcinoma is high. The positive rate of PDGF-C in patients with adenocarcinoma of papillary or alveolar type, which is positive for PDGF-C, has not been improved. However, , 2-year survival rate was significantly improved, the prognosis is good.